drugset
drugset / Trial / NCT07090031

Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer

NCT07090031 ↗

Phase 2 Active not recruiting 49 enrolled Qingdao Central Hospital
NaSingle-groupOpen-labelTreatment

Summary

5-Fluorouracil (5-FU) based chemoradiotherapy is regarded a standard perioperative treatment in locally advanced rectal cancer, but the effective rate still low. We investigate oral TAS-102 plus oxaliplatin concurrent radiotherapy for stage II or III local advanced rectal cancer.

Timeline

Start
2025-07-01
Primary completion
2027-12-01
Completion
2028-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 85 mg/m2 —
Subject TAS-102 Small molecule 35 mg/m2 Oral

Indications

No indication recorded.